#Canada #Vancouver #PTSD #Ibogaine #Optimi Health

Optimi Health Makes Significant Strides with Ibogaine Initiative

Optimi Health Corp., a leading name in the psychedelic pharmaceutical landscape, has made exciting progress with its recent Ibogaine Initiative. The Vancouver-based company has officially secured naturally derived ibogaine from two unique sources. Both hydrochloride (HCl) and freebase forms will be utilized for further development, with plans to commence the production of finished drug products this summer at their GMP facility in British Columbia, Canada.

In light of the U.S. Executive Order enacted on April 18, 2026, which prioritizes ibogaine among psychedelic therapies for accelerated FDA review and expanded patient access, Optimi's initiative couldn’t come at a more critical time. The order emphasizes the burgeoning potential of ibogaine in treating conditions such as post-traumatic stress disorder (PTSD), opioid use disorder (OUD), and traumatic brain injury (TBI). Optimi's CEO, Dane Stevens, has noted an increasing interest from research institutions, corroborated by substantial public funding, including a significant $50 million investment in Texas aimed at advancing ibogaine clinical trials.

The Development Process

The in-house development efforts will focus on standard operating procedures (SOPs) concerning the encapsulation of the finished drug product, alongside determining dosage strengths of 50mg and 100mg. This rigorous process encompasses bottling, labeling, and packaging, underpinned by validation of manufacturing and analytical testing methodologies. Optimi Health plans to share updates with stakeholders upon the program's completion.

The regulatory landscape surrounding ibogaine in Canada is notably more permissive compared to the United States. Here, ibogaine isn't categorized as a controlled substance under the Controlled Drugs and Substances Act; instead, it falls under the Food and Drugs Act and is included in Health Canada’s Prescription Drug List. This more favorable regulatory environment, coupled with Optimi's established GMP infrastructure and Health Canada licensing, positions the company uniquely to manufacture and supply ibogaine for both academic research and patient access initiatives.

Understanding Ibogaine

Ibogaine, a natural alkaloid from the root bark of the Tabernanthe iboga shrub, is increasingly regarded for its potential to disrupt opioid withdrawal symptoms and cravings, as well as its therapeutic effects on various mental health disorders including PTSD and TBI. One of the more notable studies, conducted at Stanford University, observed beneficial outcomes in U.S. Special Operations veterans who underwent ibogaine treatment, showcasing reductions in PTSD symptoms, depression, anxiety, and functional impairment.

Looking Ahead

Optimi plans to advance its ibogaine product development at its GMP facility, which is also responsible for manufacturing other psychedelic compounds like psilocybin and MDMA. With growing demand and acceptance of psychedelic therapies, Optimi appears poised for a promising future. As they continue to develop their product lines and collaborate with various clinical programs, the implications of their work reach far beyond their manufacturing efforts, touching the lives of many individuals facing significant mental health challenges.

Inquiries regarding the special access programs for ibogaine or clinical trial supplies can be directed to Optimi Health's designated email address for further information.

For the latest updates on their research and initiatives, interested parties can visit Optimi Health's website.